Heart Disease Trial, Recruiting (NCT05782777)

Heart Disease Trial, Recruiting NCT05782777 Sponsor: Yonsei University Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05782777 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged between 19 and 85 years
People who have had a heart artery-opening procedure (coronary revascularization) using a newer type of small mesh tube (drug-eluting stent) to keep the artery open

Who may not be able to join:

People who have an allergy or sensitivity to ezetimibe (a cholesterol-lowering medicine) or statins (another type of cholesterol-lowering medicine)
People with active liver disease, or whose liver enzyme blood test results (AST/ALT) have been persistently raised to more than twice the normal level without a clear explanation
People who have previously had to stop taking a statin because of a bad reaction to it
Women who are pregnant, who could potentially become pregnant, or who are currently breastfeeding
People who are not expected to live for more than 3 years
People whom the trial investigators do not expect to be able to stay involved in the study for the full year after joining
People who are unable to understand or read the informed consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 9 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Byeong-Keuk Kim, Severance Cardiovascular Hospital, Yonsei University Health System

Phone: 82-2228-8460

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05782777

Sponsor: Yonsei University

Phase: Not Applicable

Status: Recruiting

Condition: Heart Disease

Trial contact: 82-2228-8460

More information: https://clinicaltrials.gov/study/NCT05782777

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged between 19 and 85 years
People who have had a heart artery-opening procedure (coronary revascularization) using a newer type of small mesh tube (drug-eluting stent) to keep the artery open

Who may not be able to join:

People who have an allergy or sensitivity to ezetimibe (a cholesterol-lowering medicine) or statins (another type of cholesterol-lowering medicine)
People with active liver disease, or whose liver enzyme blood test results (AST/ALT) have been persistently raised to more than twice the normal level without a clear explanation
People who have previously had to stop taking a statin because of a bad reaction to it
Women who are pregnant, who could potentially become pregnant, or who are currently breastfeeding
People who are not expected to live for more than 3 years
People whom the trial investigators do not expect to be able to stay involved in the study for the full year after joining
People who are unable to understand or read the informed consent form

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Yonsei University

Registry

ClinicalTrials.gov

Start date

7 April 2023

Est. completion

1 December 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Clinical efficacy of lipid lowering therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov